Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RBC BioscienceROCO:6848 -2.29%76 EV-to-EBITDA is 12.77 as of Sep. 12, 2026, which is 1% below its 10-year median of 12.91. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$18.20 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 403 Biotechnology companies, RBC Bioscience ranks better than 50.37% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, RBC Bioscience's enterprise value is NT$672.4 Mil.
RBC Bioscience's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$52.6 Mil. Therefore, RBC Bioscience's EV-to-EBITDA for today is 12.77.
The historical rank and industry rank for RBC Bioscience's EV-to-EBITDA or its related term are showing as below:
ROCO:6848'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.11 Med: 12.91 Max: 21.29
Current: 12.77
During the past 9 years, the highest EV-to-EBITDA of RBC Bioscience was 21.29. The lowest was 2.11. And the median was 12.91.
ROCO:6848's EV-to-EBITDA is ranked better than 50.37% of 403
companies
in the Biotechnology industry
Industry Median: 13.21
vs ROCO:6848: 12.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RBC Bioscience's PE Ratio (TTM) for today is calculated as:
RBC Bioscience's share price for today is NT$21.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RBC Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for RBC Bioscience's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6848 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, RBC Bioscience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's EV-to-EBITDA falls into.
RBC Bioscience's current Enterprise Value is NT$672.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RBC Bioscience's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$52.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience (ROCO:6848) has a EV-to-EBITDA of 12.77 as of Sep. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RBC Bioscience. This is near median its historical median of 12.91. Over the past decade, RBC Bioscience's EV-to-EBITDA has ranged from 2.11 to 21.29. According to the industry distribution chart, RBC Bioscience ranks #200 out of 403 companies in the Biotechnology industry, placing it in the top 49.6%.
Is RBC Bioscience's EV-to-EBITDA too high?
RBC Bioscience's current EV-to-EBITDA of 12.77 is near median its 10-year median of 12.91. Over the past 10 years, this metric has ranged from a low of 2.11 to a high of 21.29. The Biotechnology industry median EV-to-EBITDA is 13.21. RBC Bioscience's value of 12.77 is 3.3% below this industry median. Based on the distribution chart, RBC Bioscience ranks #200 out of 403 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #200 out of 403 companies for EV-to-EBITDA. This puts RBC Bioscience in the upper half of its industry. The industry median EV-to-EBITDA is 13.21. RBC Bioscience's value of 12.77 is 3.3% below this benchmark. Historically, RBC Bioscience's own EV-to-EBITDA has ranged from 2.11 to 21.29 over the past decade. While the company's 10-year median is 12.91 vs. the industry median of 13.21, RBC Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.21, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RBC Bioscience's current EV-to-EBITDA of 12.77 is 3.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RBC Bioscience. For the Biotechnology industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RBC Bioscience's current EV-to-EBITDA is 12.77, which is near median its own 10-year median of 12.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$18.20, compared to a current price of NT$21.30 — trading 17% above its estimated fair value. The current EV-to-EBITDA is 12.77, which is near median its 10-year median of 12.91 and 3.3% below the Biotechnology industry median of 13.21. RBC Bioscience's overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current EV-to-EBITDA is 12.77 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$21.30 is trading 17% above its estimated GF Value™ of NT$18.20.
GuruFocus considers RBC Bioscience to be Modestly Overvalued.
Key valuation signals for ROCO:6848:
EV-to-EBITDA: 12.77 (near median its 10-year median of 12.91)
GF Value™: NT$18.20 vs. price of NT$21.30 (17% above fair value)
Industry Position: 3.3% below the Biotechnology median (#200 of 403)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score
Get the complete analysis for ROCO:6848
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
